Takeda Liable In IBS Drug Pay-For-Delay Trial
A Boston federal jury on Monday found Takeda Pharmaceuticals conspired with a generic drugmaker to delay the launch of a generic version of Takeda's anticonstipation drug, awarding purchasers $885 million, a figure...To view the full article, register now.
Already a subscriber? Click here to view full article